A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)

NCT07746089 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Myasthenic Syndrome
CMS

Interventions

BIOLOGICAL: Adimanebart IV
OTHER: Placebo IV

Sponsor

argenx